Carisoprodol Alternatives Compared
Carisoprodol | Cyclobenzaprine | Tizanidine |
|
---|
Carisoprodol | Cyclobenzaprine | Tizanidine |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Carisoprodol is a muscle relaxant; however, its use is limited by its potential for dependence, sedative effects, and the length of time it lasts for which means it requires dosing several times a... View more |
Cyclobenzaprine is a muscle relaxant that may be used short-term to treat muscle spasms caused by musculoskeletal conditions, in addition to rest and physical therapy. Sedation is a common side... View more |
Tizanidine relieves muscle spasms but may cause sleepiness, a drop in blood pressure, and sedation. The dosage should be individualized and because it only lasts for a short time in the body, can be... View more |
Choose a suggestion below Popular Comparisons
|
|||||||||||||||||||||||
More about Carisoprodol | More about Cyclobenzaprine | More about Tizanidine | ||||||||||||||||||||||||
Generic Status | ||||||||||||||||||||||||||
Availability | ||||||||||||||||||||||||||
Prescription only |
Prescription only |
Prescription only |
||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Carisoprodol has an average rating of 9.1 out of 10 from a total of 278 ratings on Drugs.com. 90% of reviewers reported a positive effect, while 6% reported a negative effect. |
Cyclobenzaprine has an average rating of 6.0 out of 10 from a total of 561 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 30% reported a negative effect. |
Tizanidine has an average rating of 6.2 out of 10 from a total of 320 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Commonly reported side effects include: drowsiness, sedated state. See the full carisoprodol side effects document. |
See the full cyclobenzaprine side effects document. |
Commonly reported side effects include: bradycardia, dizziness, drowsiness, hypotension, asthenia, fatigue, xerostomia. See the full tizanidine side effects document. |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all carisoprodol prices |
View all cyclobenzaprine prices |
View all tizanidine prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Soma | Amrix, Comfort Pac with Cyclobenzaprine | Zanaflex | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
8 hours |
72 hours |
2.5 hours |
||||||||||||||||||||||||
CSA Schedule** View glossary of terms | ||||||||||||||||||||||||||
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
Category B
No proven risk in humans
See the full Pregnancy Warnings document. |
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 346 drugs are known to interact with carisoprodol:
|
A total of 393 drugs are known to interact with cyclobenzaprine:
|
A total of 585 drugs are known to interact with tizanidine:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
April 09, 1959 |
August 26, 1977 |
November 27, 1996 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.